Takaki Masahiro, Tanaka Takeshi, Komohara Yoshihiro, Tsuchihashi Yoshiko, Mori Daisuke, Hayashi Kentaro, Fukuoka Junya, Yamasaki Naoya, Nagayasu Takeshi, Ariyoshi Koya, Morimoto Konosuke, Nakata Koh
Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan; Department of Infectious Diseases, Nagasaki University Hospital, Nagasaki, Japan.
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Respir Med Case Rep. 2016 Aug 13;19:89-93. doi: 10.1016/j.rmcr.2016.06.011. eCollection 2016.
Hereditary pulmonary alveolar proteinosis (PAP) caused by mutations in CSF2RA or CSF2RB, which encode GM-CSF receptor α and β respectively, is a rare disease. Although some experimental therapeutic strategies have been proposed, no clinical evidence has yet been reported. We herein describe the clinical course and recurrence of hereditary PAP after lung transplantation. A 36-year-old woman developed PAP of unknown etiology. She underwent bilateral lung transplantation from living donors at the age of 42 years because of severe respiratory failure complicated by pulmonary fibrosis. However, PAP recurred after 9 months, and we found that donor-origin alveolar macrophages had been almost completely replaced with recipient-origin macrophages. We performed a genetic analysis and identified a point deletion in the CSF2RB gene that caused a GM-CSF receptor-mediated signaling defect. PAP progressed with fibrosis in both transplanted lungs, and the patient died of respiratory failure 5 years after the lung transplantation. Distinct from recent reports on pulmonary macrophage transplantation in mice, this case suggests that human alveolar macrophages might not maintain their population only by self-renewal but may depend on a supply of precursor cells from the circulation. Bone marrow transplantation should be considered for treatment of severe PAP with GM-CSF receptor gene deficiency.
由分别编码GM-CSF受体α和β的CSF2RA或CSF2RB基因突变引起的遗传性肺泡蛋白沉积症(PAP)是一种罕见疾病。尽管已经提出了一些实验性治疗策略,但尚未有临床证据报道。我们在此描述了肺移植后遗传性PAP的临床病程和复发情况。一名36岁女性患病因不明的PAP。由于严重呼吸衰竭并发肺纤维化,她在42岁时接受了活体供者的双侧肺移植。然而,9个月后PAP复发,我们发现供者来源的肺泡巨噬细胞几乎完全被受者来源的巨噬细胞取代。我们进行了基因分析,在CSF2RB基因中鉴定出一个点缺失,该缺失导致GM-CSF受体介导的信号缺陷。PAP在双肺中随纤维化进展,患者在肺移植后5年死于呼吸衰竭。与最近关于小鼠肺巨噬细胞移植的报道不同,该病例表明人类肺泡巨噬细胞可能并非仅通过自我更新来维持其数量,而是可能依赖于循环中前体细胞的供应。对于患有GM-CSF受体基因缺陷的严重PAP患者,应考虑进行骨髓移植治疗。